ChromaDex (NASDAQ:CDXC - Free Report) had its target price lifted by HC Wainwright from $8.00 to $11.00 in a report issued on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for ChromaDex's Q1 2025 earnings at $0.03 EPS, Q2 2025 earnings at $0.04 EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.06 EPS, FY2025 earnings at $0.17 EPS, Q1 2026 earnings at $0.05 EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.08 EPS, Q4 2026 earnings at $0.11 EPS and FY2026 earnings at $0.29 EPS.
Other equities research analysts have also recently issued research reports about the stock. StockNews.com cut shares of ChromaDex from a "strong-buy" rating to a "buy" rating in a research report on Thursday, March 6th. LADENBURG THALM/SH SH increased their target price on shares of ChromaDex from $6.80 to $8.10 and gave the company a "buy" rating in a research report on Wednesday, March 5th.
View Our Latest Research Report on ChromaDex
ChromaDex Trading Down 1.4 %
Shares of CDXC traded down $0.11 during mid-day trading on Monday, hitting $7.72. The company's stock had a trading volume of 615,554 shares, compared to its average volume of 878,424. The company's 50-day moving average is $5.92 and its 200-day moving average is $5.28. ChromaDex has a 52-week low of $1.98 and a 52-week high of $9.18. The firm has a market capitalization of $600.23 million, a price-to-earnings ratio of 772.77 and a beta of 2.21.
Insider Activity at ChromaDex
In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the firm's stock in a transaction on Friday, December 13th. The shares were sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the transaction, the director now owns 244,179 shares of the company's stock, valued at approximately $1,511,468.01. This trade represents a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 9.64% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC increased its stake in shares of ChromaDex by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,154,778 shares of the company's stock worth $6,128,000 after acquiring an additional 5,186 shares during the period. D. E. Shaw & Co. Inc. increased its stake in shares of ChromaDex by 1,785.9% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,011,290 shares of the company's stock worth $5,365,000 after acquiring an additional 957,665 shares during the period. Renaissance Technologies LLC increased its stake in shares of ChromaDex by 68.0% in the fourth quarter. Renaissance Technologies LLC now owns 712,788 shares of the company's stock worth $3,781,000 after acquiring an additional 288,588 shares during the period. Arrowstreet Capital Limited Partnership increased its stake in shares of ChromaDex by 288.1% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 662,956 shares of the company's stock worth $3,517,000 after acquiring an additional 492,148 shares during the period. Finally, State Street Corp increased its stake in shares of ChromaDex by 11.3% in the third quarter. State Street Corp now owns 618,028 shares of the company's stock worth $2,256,000 after acquiring an additional 62,692 shares during the period. Hedge funds and other institutional investors own 15.41% of the company's stock.
ChromaDex Company Profile
(
Get Free Report)
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
See Also
Before you consider ChromaDex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ChromaDex wasn't on the list.
While ChromaDex currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
